-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Mineralys Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2022 to Q3 2025.
- Mineralys Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$41.1M, a 31.6% increase year-over-year.
- Mineralys Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$184M, a 9.35% decline year-over-year.
- Mineralys Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$192M, a 127% decline from 2023.
- Mineralys Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$84.7M, a 169% decline from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)